REG - Ergomed plc - Result of AGM <Origin Href="QuoteRef">ERGO.L</Origin>

ErgomedAnnouncement

27/06/2016 14:00

RNS Number : 3761C
Ergomed plc
27 June 2016
Results of 2016 Annual General Meeting
London, UK - 27 June 2016: Ergomed plc (LSE: ERGO) ('Ergomed' or 'the Company'), a profitable UK-based group dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, today announces that allresolutions put to shareholders were duly passed at its Annual General Meeting held earlier today.
The full text of all resolutions can be found in the Notice of Annual General Meeting on the Company's website www.ergomedplc.com
Enquiries:
Stifel Nicolaus Europe Limited
Tel: +44 (0) 20 7710 7600
(Nominated Adviser and Joint Broker)
Jonathan Senior / Stewart Wallace 



Numis
Tel: +44 (0) 20 7260 1000
(Joint Broker)
Michael Meade / James Black



FTI Consulting
Tel: +44 (0) 20 3727 1000
Simon Conway / Mo Noonan

About Ergomed
Founded in 1997, Ergomed plc is a profitable UK-based company, providing drug development services to the pharmaceutical industry and has a growing portfolio of co-development partnerships. It operates in over 50 countries.
Ergomed provides clinical development, trial management and pharmacovigilance services to over 100 clients ranging from top 10 pharmaceutical and generics companies to small and mid-sized drug development companies. Ergomed successfully manages clinical development from Phase I through to late phase programmes.
Ergomed has wide therapeutic expertise, with a particular focus in oncology, neurology and immunology and the development orphan drugs. Ergomed's approach to clinical trials is differentiated from that of other providers by its innovative Study Site Management model and the use of Study Physician Teams, resulting in a close relationship between Ergomed and the physicians involved in clinical trials.
As well as providing high quality clinical development services, Ergomed is building a portfolio of co-development partnerships with pharma and biotech companies. Here Ergomed shares the risks and rewards of drug development, leveraging its expertise and services in return for carried interest in the drugs under development. - a low risk investment model for potential high returns. For further information, visit: http://ergomedplc.com.
Global pharmacovigilance and medical information services are provided through its group company PrimeVigilance. www.primevigilance.com. PrimeVigilance is a specialised pharmacovigilance and medical information services provider positioned between the large clinical trials focused CROs and the smaller, local service providers who do not have the expertise or international presence needed for accurate, international safety and medical information services. 

This information is provided by RNS
The company news service from the London Stock Exchange
  END
RAGLLFEFRSIDFIR